Show simple item record

dc.contributor.authorDolly, SOen_US
dc.contributor.authorCollins, DCen_US
dc.contributor.authorSundar, Ren_US
dc.contributor.authorPopat, Sen_US
dc.contributor.authorYap, TAen_US
dc.date.accessioned2018-02-15T12:19:24Z
dc.date.issued2017-05en_US
dc.identifier.citationDrugs, 2017, 77 (8), pp. 813 - 827en_US
dc.identifier.issn0012-6667en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1102
dc.identifier.eissn1179-1950en_US
dc.identifier.doi10.1007/s40265-017-0732-2en_US
dc.description.abstractNon-small-cell lung cancer (NSCLC) remains a significant global health challenge and the leading cause of cancer-related mortality. The traditional 'one-size-fits-all' treatment approach has now evolved into one that involves personalized strategies based on histological and molecular subtypes. The molecular era has revolutionized the treatment of patients harboring epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and ROS1 gene aberrations. In the appropriately selected population, anti-tumor agents against these molecular targets can significantly improve progression-free survival. However, the emergence of acquired resistance is inevitable. Novel potent compounds with much improved and rational selectivity profiles, such as third-generation EGFR T790M resistance mutation-specific inhibitors, have been developed and added to the NSCLC armamentarium. To date, attempts to overcome resistance bypass pathways through downstream signaling blockade has had limited success. Furthermore, the majority of patients still do not harbor known driver genetic or epigenetic alterations and/or have no new available treatment options, with chemotherapy remaining their standard of care. Several potentially actionable driver aberrations have recently been identified, with the early clinical development of multiple inhibitors against these promising targets currently in progress. The advent of immune checkpoint inhibitors has led to significant benefit for advanced NSCLC patients with durable responses observed. Further interrogation of the underlying biology of NSCLC, coupled with modern clinical trial designs, is now required to develop novel targeted therapeutics rationally matched with predictive biomarkers of response, so as to further advance NSCLC therapeutics through the next decade.en_US
dc.formatPrinten_US
dc.format.extent813 - 827en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectHumansen_US
dc.subjectCarcinoma, Non-Small-Cell Lungen_US
dc.subjectLung Neoplasmsen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectDrug Resistance, Neoplasmen_US
dc.subjectDrug Discoveryen_US
dc.subjectMolecular Targeted Therapyen_US
dc.subjectBiomarkers, Tumoren_US
dc.titleAdvances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1007/s40265-017-0732-2en_US
rioxxterms.licenseref.startdate2017-05en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfDrugsen_US
pubs.issue8en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume77en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMedicine Drug Development Unit (de Bono)en_US
icr.researchteamThoracic Oncologyen_US
dc.contributor.icrauthorPopat, Sanjayen_US
dc.contributor.icrauthorYap, Timothyen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record